Protocol Ledger

NCT07816367 · Phase III · RECRUITING

A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

Interventional Phase III clinical trial protocol NCT07816367 sponsored by TriGemX Bio in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-10-02 Enrollment: 1,500 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07816367
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,500 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07816367
Protocol FieldVerified Registry Value
NCT IdentifierNCT07816367
Consolidated Lead SponsorTriGemX Bio
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment1,500 participants (ESTIMATED)
Registered Start Date2026-10-02
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI